Advanced Search

 

Study ID Status Title Patient Level Data
263855/034 Completed Double-blind, randomized, phase III clinical trial to evaluate the immunogenicity and reactogenicity of three consecutive doses of dTpa, or of dTpa-IPV followed by two doses of Td vaccine , and compared to three consecutive doses of Td vaccine administered to healthy adults in a 0,1,6-month schedule Study Listed on ClinicalStudyDataRequest.com
263855/035 Terminated Phase IIIb study to evaluate immunogenicity, antibody persistency and reactogenicity of DTPa - INFANRIX and dTpa - BOOSTRIX vaccines administered to healthy children previously primed with 3 doses of DTPa vaccine compared to placebo (HAVRIX®JUNIOR) Study Listed on ClinicalStudyDataRequest.com
270362/006 Completed A phase III, open, randomized, multicentric study to compare the reactogenicity and immunogenicity of GSK Biologicals’ combined Vi polysaccharide typhoid vaccine and inactivated Hepatitis A vaccine, to that elicited by GSK Biologicals’ Hepatitis A vaccine, administered singly or concomitantly with GSK Biologicals’ Vi polysaccharide vaccine Study Listed on ClinicalStudyDataRequest.com
287615/005 Completed Safety and the efficacy of GSK Biologicals' candidate adjuvanted vaccines (287615) containing HBsAg with various adjuvants to induce cytotoxic T lymphocytes (CTL) in healthy adult volunteers
29060/799 Completed BRL29060A in Posttraumatic Stress Disorder
29060/874 Completed A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Evaluating the Efficacy and Safety of Paroxetine CR in Elderly Outpatients Diagnosed with Major Depressive Disorder Study Listed on ClinicalStudyDataRequest.com
347414/010 Terminated Assess, in young children, the efficacy in preventing acute otitis media (AOM) of GSK Biologicals undecavalent pneumococcal-protein D conjugate vaccine, when administered as a three dose primary vaccination course during the first year of life with a booster dose in the second year of life. Study Listed on ClinicalStudyDataRequest.com
393229/005 Completed Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma
393229/007 Completed Phase II Multicenter Study of Iodine-131 Anti-B1 Antibody Consolidation For Patients With Diffuse Large B-Cell Non-Hodgkin’s Lymphoma Following First-line CHOP Study Listed on ClinicalStudyDataRequest.com
393229/010 Completed Retreatment Study of Patients with Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody Study Listed on ClinicalStudyDataRequest.com
393229/023 Completed Fludarabine monophosphate followed by Iodine I 131 Tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma Study Listed on ClinicalStudyDataRequest.com
393229/027 Completed A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma Study Listed on ClinicalStudyDataRequest.com
393229/028 Completed A Multi-Center, Randomized, Phase 3 Study of Rituximab versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma Study Listed on ClinicalStudyDataRequest.com
393229/029 Withdrawn A Multi-center, Randomized, Phase 3 Study of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen for Patients with Relapsed or Transformed Follicular Non-Hodgkin's Lymphoma
393229/032 Completed A single arm, open-label, multicentre, phase II study of Tositumomab and Iodine 131-Tositumomab in subjects with indolent non-Hodgkin's Lymphoma who have previously received Rituximab. Study Listed on ClinicalStudyDataRequest.com
398149 Completed None
424323/025 Completed ThromboEMbolism Prevention Efficacy and Safety Trial (TEMPEST): A Double-blind Four-week Study to Assess the Efficacy, Safety, and Tolerability of SB-424323 in the Extended Prophylaxis of Patients Following Total Hip Arthroplasty
444563/004 Completed A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants. Study Listed on ClinicalStudyDataRequest.com
444563/005 Completed Phase II, double-blind, randomized, placebo-controlled study of 2 doses of GSK Biologicals’ live attenuated human rotavirus vaccine at different virus concentrations (10 5.2 and 10 6.4 ffu) in healthy infants following a 0, 2 month schedule and previously uninfected with human rotavirus. Study Listed on ClinicalStudyDataRequest.com
444563/006 Completed To assess the efficacy, immuno & safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months & previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. Study Listed on ClinicalStudyDataRequest.com
444563/007 Completed Study to assess efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus vaccine at different viral concentrations in healthy infants previously uninfected with human rotavirus and approximately 3 months of age. Study Listed on ClinicalStudyDataRequest.com
444563/013 Completed A phase II, randomized, double-blind, placebo-controlled study of safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine at 10E6.5 CCID50 viral concentration in healthy infants (approximately 5-10 weeks old) in the Republic of South Africa Study Listed on ClinicalStudyDataRequest.com
444563/014 Completed Reactogenicity & immunogenicity study of two doses of GSK Biologicals’ oral live attenuated HRV vaccine co-administered with either OPV or IPV in healthy infants (approximately 5-10 weeks old) in South Africa Study Listed on ClinicalStudyDataRequest.com
444563/022 Completed A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine Study Listed on ClinicalStudyDataRequest.com
444563/023 Completed A placebo-controlled, multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.